BioPharmSignal logoBioPharmSignal

Biotech News

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Praxis Precision Medicines (PRAX)Praxis Precision MedicinesFDA / regulatory

FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S.

Related news

PRAXPraxis Precision Medicines2026-06-22 12:00 EST

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

PRAXPraxis Precision Medicines2026-07-07 12:00 EST

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

AXSMAxsome2026-07-15 11:00 EST

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

TEVATeva Pharmaceutical Industries2026-08-28 10:17 EST

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

CGTXCognition Therapeutics2026-06-24 11:30 EST

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

XENEXenon2026-09-17 20:01 EST

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

XERSXeris Pharmaceuticals2026-09-09 12:30 EST

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

TEVATeva Pharmaceutical Industries2026-08-19 12:30 EST

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

ACIUAC Immune2026-08-11 11:00 EST

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

View all latest news

Praxis Precision Medicines

Precision Neuroscience Praxis Precision Medicines develops therapies for genetically and physiologically defined disorders of neuronal excitation. Its pipeline spans movement disorders and developmental epilepsies. Ulixacaltamide Ulixacaltamide is a small-molecule T-type calcium-channel modulator under FDA review for essential...

Recent company news

PRAXPraxis Precision Medicines2026-09-03 20:01 EST

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRAXPraxis Precision Medicines2026-08-06 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PRAXPraxis Precision Medicines2026-08-04 20:01 EST

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRAXPraxis Precision Medicines2026-07-30 20:01 EST

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

PRAXPraxis Precision Medicines2026-07-07 12:00 EST

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

Stock data

Close
298.95 USD
Market cap
7.19B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States